Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Tuesday, September 8, 2026.
Forward PE Ratio (N/A) = Close Price ($146.79) / Consensus Forward EPS ($-0.46)
FORWARD PE RATIO
N/A
Gilead Sciences, Inc.
Market Cap
$182.25B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Gilead Sciences, Inc. (GILD) | $182.25B | N/A |
| Abbott Laboratories (ABT)vs › | $182.92B | 19.64 |
| Novo Nordisk A/S (NVO)vs › | $201.12B | N/A |
| Pfizer Inc. (PFE)vs › | $158.76B | 9.57 |
| Amgen Inc. (AMGN)vs › | $213.83B | 18.95 |
| Danaher Corporation (DHR)vs › | $144.93B | 24.42 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.73B | 24.44 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.42B | 29.13 |
| Bristol-Myers Squibb Company (BMY)vs › | $132.02B | 9.64 |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.92B | 33.96 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $146.79 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.46 | $-0.62 – $-0.32 | 16 | n/m |
| 2027-12-31 | $9.89 | $9.38 – $11.06 | 16 | 14.8x |
| 2028-12-31 | $10.66 | $9.15 – $12.18 | 10 | 13.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
